161 related articles for article (PubMed ID: 20884687)
1. An update on the efficacy and safety of aclidinium bromide in patients with COPD.
Alagha K; Bourdin A; Tummino C; Chanez P
Ther Adv Respir Dis; 2011 Feb; 5(1):19-28. PubMed ID: 20884687
[TBL] [Abstract][Full Text] [Related]
2. Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile.
Gavaldà A; Miralpeix M; Ramos I; Otal R; Carreño C; Viñals M; Doménech T; Carcasona C; Reyes B; Vilella D; Gras J; Cortijo J; Morcillo E; Llenas J; Ryder H; Beleta J
J Pharmacol Exp Ther; 2009 Nov; 331(2):740-51. PubMed ID: 19710368
[TBL] [Abstract][Full Text] [Related]
3. Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.
Sentellas S; Ramos I; Albertí J; Salvà M; Antón F; Miralpeix M; Beleta J; Gavaldà A
Eur J Pharm Sci; 2010 Mar; 39(5):283-90. PubMed ID: 20093184
[TBL] [Abstract][Full Text] [Related]
4. The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease.
Maltais F; Milot J
Ther Adv Respir Dis; 2012 Dec; 6(6):345-61. PubMed ID: 23075544
[TBL] [Abstract][Full Text] [Related]
5. The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide.
Gavaldà A; Ramos I; Carcasona C; Calama E; Otal R; Montero JL; Sentellas S; Aparici M; Vilella D; Alberti J; Beleta J; Miralpeix M
Pulm Pharmacol Ther; 2014 Aug; 28(2):114-21. PubMed ID: 24928173
[TBL] [Abstract][Full Text] [Related]
6. Aclidinium bromide, a novel long-acting muscarinic antagonist for COPD with improved preclinical renal and urinary safety profile.
Gavaldà A; Gras J; Llupià J; Aubets J; Beleta J; Llenas J
Life Sci; 2012 Feb; 90(7-8):301-5. PubMed ID: 22213116
[TBL] [Abstract][Full Text] [Related]
7. Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients.
Joos GF; Schelfhout VJ; Pauwels RA; Kanniess F; Magnussen H; Lamarca R; Jansat JM; Garcia Gil E
Respir Med; 2010 Jun; 104(6):865-72. PubMed ID: 20044242
[TBL] [Abstract][Full Text] [Related]
8. Aclidinium bromide, a novel long-acting muscarinic M3 antagonist for the treatment of COPD.
Cazzola M
Curr Opin Investig Drugs; 2009 May; 10(5):482-90. PubMed ID: 19431081
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I).
Kerwin EM; D'Urzo AD; Gelb AF; Lakkis H; Garcia Gil E; Caracta CF;
COPD; 2012 Apr; 9(2):90-101. PubMed ID: 22320148
[TBL] [Abstract][Full Text] [Related]
10. Safety and pharmacokinetics of multiple doses of aclidinium bromide, a novel long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease, in healthy participants.
Jansat JM; Lamarca R; de Miquel G; Schrödter A; Miletzki B; Gurniak M
J Clin Pharmacol; 2009 Oct; 49(10):1239-46. PubMed ID: 19592595
[TBL] [Abstract][Full Text] [Related]
11. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Gupta V; Singh D
Expert Rev Respir Med; 2012 Dec; 6(6):581-8. PubMed ID: 23234445
[TBL] [Abstract][Full Text] [Related]
12. Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease.
Woods JA; Nealy KL; Barrons RW
Ann Pharmacother; 2013; 47(7-8):1017-28. PubMed ID: 23737515
[TBL] [Abstract][Full Text] [Related]
13. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Joos GF
Drugs Today (Barc); 2012 Dec; 48(12):757-63. PubMed ID: 23243632
[TBL] [Abstract][Full Text] [Related]
14. Profile of aclidinium bromide in the treatment of chronic obstructive pulmonary disease.
Sims MW; Panettieri RA
Int J Chron Obstruct Pulmon Dis; 2011; 6():457-66. PubMed ID: 22003291
[TBL] [Abstract][Full Text] [Related]
15. Aclidinium bromide for the treatment of chronic obstructive pulmonary disease.
Cazzola M; Page CP; Matera MG
Expert Opin Pharmacother; 2013 Jun; 14(9):1205-14. PubMed ID: 23566013
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of long-acting muscarinic antagonists: comparison of tiotropium and investigational drugs.
Casarosa P; Bouyssou T; Germeyer S; Schnapp A; Gantner F; Pieper M
J Pharmacol Exp Ther; 2009 Aug; 330(2):660-8. PubMed ID: 19478135
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide (aclidinium bromide).
Prat M; Fernández D; Buil MA; Crespo MI; Casals G; Ferrer M; Tort L; Castro J; Monleón JM; Gavaldà A; Miralpeix M; Ramos I; Doménech T; Vilella D; Antón F; Huerta JM; Espinosa S; López M; Sentellas S; González M; Albertí J; Segarra V; Cárdenas A; Beleta J; Ryder H
J Med Chem; 2009 Aug; 52(16):5076-92. PubMed ID: 19653626
[TBL] [Abstract][Full Text] [Related]
18. Onset of effect of aclidinium, a novel, long-acting muscarinic antagonist, in patients with COPD.
Vestbo J; Vogelmeier C; Creemers J; Falques M; Ribera A; Gil EG
COPD; 2010 Oct; 7(5):331-6. PubMed ID: 20854047
[TBL] [Abstract][Full Text] [Related]
19. Clinical potential of aclidinium bromide in chronic obstructive pulmonary disease.
Jones PW
Int J Chron Obstruct Pulmon Dis; 2015; 10():677-87. PubMed ID: 25848244
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of aclidinium administered intravenously and absolute bioavailability of inhaled aclidinium in healthy male participants.
Ortiz S; Flach S; Caracta C; Gil EG; Jansat JM
J Clin Pharmacol; 2012 Jun; 52(6):819-27. PubMed ID: 21628603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
